Study of RP-3500, Camonsertib, in Advanced Solid Tumors

NCT04497116 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

276

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: RP-3500 (camonsertib)
DRUG: Talazoparib
DRUG: Gemcitabine Injection

Sponsor

Repare Therapeutics